Evidence map›Paper›PMID 23518152›Full record

ArticleNeuroscience letters2013

NMDA receptor-dependent glutamate excitotoxicity in human embryonic stem cell-derived neurons.

Kunal Gupta, Giles E Hardingham, Siddharthan Chandran

Open access · hybridAbstract read
In one paragraph

Article in Neuroscience letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Modulation of CaScientific reports · 2024
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Kunal GuptaCambridge Centre for Brain Repair, University of Cambridge, Cambridge CB2 0SZ, United Kingdom. kg244@cantab.net
Giles E Hardingham
Siddharthan Chandran
University of Edinburgh · GBUniversity of Cambridge · GB

Funding

Biotechnology and Biological Sciences Research CouncilMedical Research Council G0902044Wellcome Trust
6 · The paper itself

Abstract

Thanks to the development of efficient differentiation strategies, human pluripotent stem cells (HPSC) offer the opportunity for modelling neuronal injury and dysfunction in human neurons in vitro. Critically, the effective use of HPSC-derived neural cells in disease-modelling and potentially cell replacement therapies hinges on an understanding of the biology of these cells, specifically their development, subtype specification and responses to neurotoxic signalling mediators. Here, we generated neurons from human embryonic stem cells and characterised the development of vulnerability to glutamate excitotoxicity, a key contributor to neuronal injury in several acute and chronic neurodegenerative disorders. Over two months of differentiation we observed a gradual increase in responsiveness of neurons to glutamate-induced Ca(2+) influx, attributable to NMDA receptor activity. This increase was concomitant with an increase in expression of mRNA encoding NMDA and AMPA receptor subunits. Differentiated neurons were vulnerable to glutamate excitotoxicity in a dose-dependent manner, which was reduced by NMDA receptor antagonists.

Indexed as

Cell DeathCell DifferentiationCells, CulturedDizocilpine MaleateEmbryonic Stem CellsGlutamic AcidHumansNeuronsProtein SubunitsReceptors, AMPAReceptors, N-Methyl-D-AspartateTime FactorsDizocilpine MaleateGlutamic AcidProtein SubunitsReceptors, AMPAReceptors, N-Methyl-D-Aspartate

Identifiers

PMID23518152
PMCPMC3725411
OpenAlexW2164947605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.